Clinical trials sponsored by Tianjin Medical University Cancer Institute and Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Tianjin Medical University Cancer Institute and Hospital

• A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
  NCT06760364 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
  NCT06878625 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
  NCT07548060 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
  NCT07506109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
  NCT07358676 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
  NCT05890287 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
  NCT07019233 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
  NCT05035147 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
  NCT06939127 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
  NCT06498154 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
  NCT07561567 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  NCT07304739 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
  NCT07047560 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
  NCT04631770 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
  NCT07528274 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
  NCT06363734 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
  NCT05686434 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
  NCT06852287 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
  NCT06141226 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
  NCT06454448 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
  NCT06951997 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
  NCT07632118 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Real-world Studies of CDK4/6 Inhibitors
  NCT07407439 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Second-line Immunotherapy for ES-SCLC
  NCT06853678 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
  NCT07594925 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
  NCT07058948 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
  NCT07436741 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
  NCT07330037 · Phase: Phase 2 · Ages: 17 Years to 75 Years · Sex: All (male and female) · 1 location
• To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
  NCT06352008 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
  NCT06721286 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Tianjin Medical University Cancer Institute and Hospital recruiting for?

Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 31 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.